PDE inhibitors are a class of drugs that inhibit the activity of phosphodiesterase enzymes. PDEs are found in many tissues and organs, including the heart, lungs, kidneys, and brain. They regulate the levels of cyclic adenosine monophosphate (cAMP) in cells by breaking down cAMP to inactive 5'AMP. PDE inhibitors work by blocking this breakdown process and increasing cAMP levels. This increases blood flow to certain areas of the body such as the penis or clitoris for erectile dysfunction or vaginal dryness respectively.
-The market for PDE inhibitors is expected to grow at a CAGR of 4.5% from 2017 to 2022.
-PDE inhibitors are used in the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, and erectile dysfunction.
Industry Growth Insights published a new data on “Phosphodiesterase (PDE) inhibitors Market”. The research report is titled “Phosphodiesterase (PDE) inhibitors Market research by Types (PDE1 Selective Inhibitors, PDE2 Selective Inhibitors, PDE3 Selective Inhibitors, PDE4 selective inhibitors, PDE5 selective inhibitors, PDE7 selective inhibitors, PDE10 selective inhibitors), By Applications (Oral, Topical, Other), By Players/Companies Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Phosphodiesterase (PDE) inhibitors Market Research Report
By Type
PDE1 Selective Inhibitors, PDE2 Selective Inhibitors, PDE3 Selective Inhibitors, PDE4 selective inhibitors, PDE5 selective inhibitors, PDE7 selective inhibitors, PDE10 selective inhibitors
By Application
Oral, Topical, Other
By Companies
Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
 inhibitors Industry Outlook.svg)
Global Phosphodiesterase (PDE) inhibitors Market Report Segments:
The global Phosphodiesterase (PDE) inhibitors market is segmented on the basis of:
Types
PDE1 Selective Inhibitors, PDE2 Selective Inhibitors, PDE3 Selective Inhibitors, PDE4 selective inhibitors, PDE5 selective inhibitors, PDE7 selective inhibitors, PDE10 selective inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oral, Topical, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Pfizer Inc.
- Vivus Inc.
 inhibitors Market Overview.svg)
Highlights of The Phosphodiesterase (PDE) inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PDE1 Selective Inhibitors
- PDE2 Selective Inhibitors
- PDE3 Selective Inhibitors
- PDE4 selective inhibitors
- PDE5 selective inhibitors
- PDE7 selective inhibitors
- PDE10 selective inhibitors
- By Application:
- Oral
- Topical
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Phosphodiesterase (PDE) inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Phosphodiesterase inhibitors (PDEIs) are medications that block the action of phosphodiesterase, an enzyme that breaks down phospholipids. PDEIs can improve blood flow and sexual function in men with erectile dysfunction (ED) and women with female sexual dysfunction (FSD).
Some of the major companies in the phosphodiesterase (pde) inhibitors market are Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc..
The phosphodiesterase (pde) inhibitors market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Phosphodiesterase (PDE) inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Phosphodiesterase (PDE) inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Phosphodiesterase (PDE) inhibitors Market - Supply Chain
4.5. Global Phosphodiesterase (PDE) inhibitors Market Forecast
4.5.1. Phosphodiesterase (PDE) inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Phosphodiesterase (PDE) inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Phosphodiesterase (PDE) inhibitors Market Absolute $ Opportunity
5. Global Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
5.3.1. PDE1 Selective Inhibitors
5.3.2. PDE2 Selective Inhibitors
5.3.3. PDE3 Selective Inhibitors
5.3.4. PDE4 selective inhibitors
5.3.5. PDE5 selective inhibitors
5.3.6. PDE7 selective inhibitors
5.3.7. PDE10 selective inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
6.3.1. Oral
6.3.2. Topical
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Phosphodiesterase (PDE) inhibitors Demand Share Forecast, 2019-2026
9. North America Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
9.4.1. Oral
9.4.2. Topical
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
9.7.1. PDE1 Selective Inhibitors
9.7.2. PDE2 Selective Inhibitors
9.7.3. PDE3 Selective Inhibitors
9.7.4. PDE4 selective inhibitors
9.7.5. PDE5 selective inhibitors
9.7.6. PDE7 selective inhibitors
9.7.7. PDE10 selective inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Phosphodiesterase (PDE) inhibitors Demand Share Forecast, 2019-2026
10. Latin America Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
10.4.1. Oral
10.4.2. Topical
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
10.7.1. PDE1 Selective Inhibitors
10.7.2. PDE2 Selective Inhibitors
10.7.3. PDE3 Selective Inhibitors
10.7.4. PDE4 selective inhibitors
10.7.5. PDE5 selective inhibitors
10.7.6. PDE7 selective inhibitors
10.7.7. PDE10 selective inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Phosphodiesterase (PDE) inhibitors Demand Share Forecast, 2019-2026
11. Europe Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
11.4.1. Oral
11.4.2. Topical
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
11.7.1. PDE1 Selective Inhibitors
11.7.2. PDE2 Selectie Inhibitors
11.7.3. PDE3 Selective Inhibitors
11.7.4. PDE4 selective inhibitors
11.7.5. PDE5 selective inhibitors
11.7.6. PDE7 selective inhibitors
11.7.7. PDE10 selective inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Phosphodiesterase (PDE) inhibitors Demand Share, 2019-2026
12. Asia Pacific Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
12.4.1. Oral
12.4.2. Topical
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
12.7.1. PDE1 Selective Inhibitors
12.7.2. PDE2 Selective Inhibitors
12.7.3. PDE3 Selective Inhibitors
12.7.4. PDE4 selective inhibitors
12.7.5. PDE5 selective inhibitors
12.7.6. PDE7 selective inhibitors
12.7.7. PDE10 selective inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Phosphodiesterase (PDE) inhibitors Demand Share, 2019-2026
13. Middle East & Africa Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Application
13.4.1. Oral
13.4.2. Topical
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Phosphodiesterase (PDE) inhibitors Market Size and Volume Forecast by Type
13.7.1. PDE1 Selective Inhibitors
13.7.2. PDE2 Selective Inhibitors
13.7.3. PDE3 Selective Inhibitors
13.7.4. PDE4 selective inhibitors
13.7.5. PDE5 selective inhibitors
13.7.6. PDE7 selective inhibitors
13.7.7. PDE10 selective inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Phosphodiesterase (PDE) inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Phosphodiesterase (PDE) inhibitors Market: Market Share Analysis
14.2. Phosphodiesterase (PDE) inhibitors Distributors and Customers
14.3. Phosphodiesterase (PDE) inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Co.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Vivus Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
